pharmaceutical investing Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
pharmaceutical investing Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
pharmaceutical investing Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
pharmaceutical investing Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
pharmaceutical investing Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding
CoTec to Form an Early Stage Exploration Joint Venture with U.S. Company Copper Intelligence to Target Processing Historical Copper Tailings Opportunities in the Democratic Republic of Congo
Analyst Note: Positive PEA Delivered - Rua Gold's Auld Creek Enters PFS Workstream Under New Zealand Fast-Track Approvals
Analyst Note: Positive PEA Delivered - Rua Gold's Auld Creek Enters PFS Workstream Under New Zealand Fast-Track Approvals
